Skip to main content

Advertisement

SpringerLink
Log in

The use of mycophenolate mofetil in experimental encapsulating peritoneal sclerosis

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Introduction

Encapsulated peritoneal sclerosis (EPS) is a rare complication of long-term peritoneal dialysis usually associated with the inadequacy and early termination of dialysis modality. Adequate treatment of peritoneal fibrosis has not been achieved by medical intervention so far. Mycophenolate mofetil (MMF), which inhibits inosine monophosphate dehydrogenase reversibly and highly selectively, is the most widely used drug for maintenance immunosupression in renal transplantation. Recent studies have shown that MMF has also antifibrotic effects. In this study, we evaluated the effects of MMF on EPS model in rats based on antifibrotic effects.

Materials and methods

Twenty-four Wistar albino rat have been randomly divided into four groups. Group I (control group) received isotonic saline intraperitoneally (i.p) 2 ml/day for (0–3rd weeks). Group II (chlorhexidine (CG) group) received CG 2 ml/day i.p. for (0–3rd weeks). Group III (chlorhexidine + MMF group) received CG (2 ml/day) i.p. for (0–3rd weeks) plus MMF 30 mg/kg/day peroral (4th–6th weeks). Group IV (resting group) received CG 2 ml/day) i.p. (0–3rd weeks) plus peritoneal resting without any treatment (4th–6th weeks) At the end of the sixth weeks, all of the rats were killed. All of the groups were analyzed in terms of peritoneal thickness, degree of inflammation, vasculopathy, neovascularization and fibrosis. Also, the parietal peritoneal tissue samples were evaluated for matrix metalloproteinase 2 (MMP-2) by using the immunohistochemical analysis.

Results

When the CG group was compared with the MMF group, the medication resulted in a statistically significant reduction in peritoneal thickness, inflammation and fibrosis score (53.23 ± 16.24 vs. 17.22 ± 3.62, 1 ± 1.225 vs. 1 ± 0, 1.6 ± 0.548 vs. 0.2 ± 0.447, respectively, all p < 0.05). In the resting group, no beneficial effects on morphological abnormality of the peritoneum were observed as compared with MMF group. However, according to immunohistochemical analysis of the expression of MMP-2 on peritoneal samples, the highest expression of MMP-2 was observed in the MMF group.

Conclusion

MMF was effective for the treatment of encapsulating peritoneal fibrosis in our rat model. Most recently, MMF may be first choice for EPS due to antifibrotic effect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ertilav M, Timur O, Hür E, Bozkurt D, Nar H, Kologlu T, Sen S, Duman S (2011) What does the dialysate level of matrix metalloproteinase 2 tell us? Adv Perit Dial 27:6–10

    PubMed  Google Scholar 

  2. Krediet RT (2007) 30 years of peritoneal dialysis development: the past and the future. Perit Dial Int 27(suppl 2):35–41

    Google Scholar 

  3. Hirahara I, Inoue M, Okuda K, Ando Y, Muto S, Kusano E (2007) The potential of matrix metalloproteinase–2 as a marker of peritoneal injury increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis–a multicentre study in Japan. Nephrol Dial Transplant 22:560–567

    Article  CAS  PubMed  Google Scholar 

  4. Nakamoto H (2005) Encapsulating peritoneal sclerosis–a clinician’s approach to diagnosis and medical treatment. Perit Dial Int 25(Suppl 4):30–38

    Google Scholar 

  5. Wong CF, Beshir S, Khalil A, Pai P, Ahmad R (2005) Successful treatment of encapsulating peritoneal sclerosis with azathioprine and prednisolone. Perit Dial Int 25:285–287

    PubMed  Google Scholar 

  6. Lafrance JP, Létourneau I, Ouimet D, Bonnardeaux A, Leblanc M, Mathieu N, Pichette V (2008) Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy. Am J Kidney Dis 51:7–10

    Article  Google Scholar 

  7. Fieren MW, Betjes MG, Korte MR, Boer WH (2007) Posttransplant encapsulating peritoneal sclerosis: a worrying new trend? Perit Dial Int 27:619–624

    PubMed  Google Scholar 

  8. Jiang S, Tang Q, Rong R, Tang L, Xu M, Lu J, Jia Y, Ooi Y, Hou J, Guo J, Yang B, Zhu T (2012) Mycophenolate mofetil inhibits macrophage infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. Eur J Pharmacol 688(1–3):56–61

    Article  CAS  PubMed  Google Scholar 

  9. Ishii Y, Sawada T, Shimizu A, Tojimbara T, Nakajima I, Fuchinoue S et al (2001) An experimental sclerosing encapsulating peritonitis model in mice. Nephrol Dial Transplant 16:1262–1266

    Article  CAS  PubMed  Google Scholar 

  10. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR et al (2002) Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 13:470–479

    PubMed  Google Scholar 

  11. Ascherman DP (2010) Interstitial lung disease in rheumatoid arthritis. Curr Rheumatol Rep 12:363–369

    Article  PubMed  Google Scholar 

  12. Koukoulaki M, Goumenos DS (2010) The accumulated experience with the use of mycophenolate mofetil in primary glomerulonephritis. Expert Opin Investig Drugs 19:673–687

    Article  CAS  PubMed  Google Scholar 

  13. Antic M, Distler JH, Distler O (2013) Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise? Curr Opin Pharmacol 13:455–462

    Article  CAS  PubMed  Google Scholar 

  14. Roos N, Poulalhon N, Farge D, Madelaine I, Mauviel A, Verrecchia F (2007) In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther 321:583–589

    Article  CAS  PubMed  Google Scholar 

  15. Waller JR, Brook NR, Bicknell GR, Murphy GJ, Nicholson ML (2005) Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration. Transplant Proc 37:164–166

    Article  CAS  PubMed  Google Scholar 

  16. Hur E, Bozkurt D, Timur O, Bicak S, Sarsik B, Akcicek F, Duman S (2012) The effects of mycophenolate mofetil on encapsulated peritoneal sclerosis model in rats. Clin Nephrol 77:1–7

    Article  CAS  PubMed  Google Scholar 

  17. Masunaga Y, Hirahara I, Shimano Y, Kurosu M, Iimura O, Miyata Y, Amemiya M, Homma S, Kusano E, Asano Y (2005) A case of encapsulating peritoneal sclerosis at the clinical early stage with high concentration of matrix metalloproteinase-2 in peritoneal effluent. Clin Exp Nephrol 9:85–89

    Article  PubMed  Google Scholar 

  18. Hirahara I, Ogawa Y, Kusano E, Asano Y (2004) Activation of matrix metalloproteinase-2 causes peritoneal injury during peritoneal dialysis in rats. Nephrol Dial Transplant 19:1732–1741

    Article  CAS  PubMed  Google Scholar 

  19. Barreto DL, Coester AM, Struijk DG, Krediet RT (2013) Can effluent matrix metalloproteinase 2 and plasminogen activator inhibitor 1 be used as biomarkers of peritoneal membrane alterations in peritoneal dialysis patients? Perit Dial Int 33:529–537

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

We have no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Author information

Authors and Affiliations

  1. Department of Nephrology, Ankara Education and Research Hospital, Ankara, Turkey

    Bülent Huddam, Alper Azak, Funda Yalçın & Murat Duranay

  2. Department of Internal Medicine, Ankara Education and Research Hospital, Ankara, Turkey

    Murat Başaran

  3. Department of Nephrology, Faculty of Medicine, Çanakkale Onsekiz Mart University, Hamidiye Mah. Ulus Sok. Zeytinevleri Sitesi, A Blok, No:12, Çanakkale, Turkey

    Gülay Koçak

  4. Department of Pathology, Faculty of Medicine, Başkent University, Ankara, Turkey

    Nihan Haberal Reyhan

Authors
  1. Bülent Huddam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Murat Başaran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gülay Koçak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alper Azak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Funda Yalçın
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nihan Haberal Reyhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Murat Duranay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gülay Koçak.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huddam, B., Başaran, M., Koçak, G. et al. The use of mycophenolate mofetil in experimental encapsulating peritoneal sclerosis. Int Urol Nephrol 47, 1423–1428 (2015). https://doi.org/10.1007/s11255-015-1015-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-015-1015-z

Keywords

Search

Navigation